Mizuki Nishino

Brigham and Women's Hospital — United States

Medicine · Health Sciences

79h-index23.8kcitations819works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(447), Cancer Genomics and Diagnostics(139), Cancer Immunotherapy and Biomarkers(122), RNA modifications and cancer(114), Colorectal Cancer Treatments and Studies(104)

Publications819 total

Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S8 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Automated interstitial lung abnormalities detection at CT: external validation and potential recognition of traction bronchiectasis/bronchiolectasis
Japanese Journal of Radiology·2025Open Access
Supplementary Figure S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S9 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S7 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S10 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure 21 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure 22. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure 3 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
2025Open Access
page 1 of 41Next →

Frequent Co-authors

Hiroto Hatabu(22), Lynette M. Sholl(15), Mark M. Awad(14), Pasi A. Jänne(11), Nikhil H. Ramaiya(10), F. Stephen Hodi(10), Iván O. Rosas(10), Biagio Ricciuti(9), George R. Washko(8), Gary M. Hunninghake(8), Bruce E. Johnson(6), Matthew D. Hellmann(5), John V. Heymach(5), Yuka Okajima(5), James C. Ross(5), Raúl San Jośe Estépar(5), Tetsuro Araki(5), Joao V. Alessi(5), Yvonne Y. Li(5), Gonzalo Recondo(5)